UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): February 7, 2007
NxSTAGE MEDICAL, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
000-51567
(Commission File Number)
|
|
04-3454702
(I.R.S. Employer Identification No.) |
|
|
|
439 South Union Street, 5th Floor
Lawrence, MA
(Address of principal executive offices)
|
|
01843
(Zip Code) |
(978) 687-4700
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
Preferred Service Provider Agreement
On
February 7, 2007, NxStage Medical, Inc. (NxStage) entered into a National Service
Provider Agreement (the Agreement) with DaVita Inc.
(DaVita), NxStage's largest customer. Pursuant to the terms of the
Agreement, NxStage grants DaVita certain market rights for the NxStage System One
and related supplies for home hemodialysis therapy. DaVita is granted
exclusive rights in a small percentage of geographies, which
geographies collectively represent less than ten percent (10%) of the U.S. ESRD
patient population, and limited exclusivity in the majority of
all other U.S. geographies,
subject to DaVitas meeting certain requirements, including patient volume commitments and new
patient training rates. If certain minimum patient numbers or training rates are not achieved,
DaVita can lose all or part of its preferred geographic rights. The Agreement limits, but does
not prohibit, the sale by NxStage of the NxStage System One for chronic patient home hemodialysis
therapy to any provider that is under common control or management of a parent entity that
collectively provides dialysis services to more than 25% of U.S. chronic dialysis patients and that
also supplies dialysis products.
The
Agreement has an initial term of three years, terminating on
December 31, 2009, and DaVita has the option of renewing the
Agreement for four additional periods of six months if DaVita meets certain patient volume targets.
Under
the Agreement, DaVita commits to purchase all of its existing NxStage System One equipment
currently being rented from NxStage (for a purchase price of
approximately $5 million) and to buying a significant percentage
of its future System One equipment needs. DaVita is granted most
favored nations pricing for the products purchased under the
Agreement provided DaVita achieves certain obligations, including certain patient volume targets.
Further, the Agreement contemplates certain collaborations between the parties, including efforts
dedicated towards advancing market awareness of NxStage therapies and home and more frequent
hemodialysis.
Either party may terminate the Agreement if the other party becomes the subject of bankruptcy
or similar proceedings or loses its eligibility to bill for services under the Medicare or Medicaid
programs.
Stock Purchase Agreement
In
connection with the National Service Provider Agreement, on February 7, 2007,
NxStage issued and sold to DaVita 2,000,000 shares (the Shares) of common stock, $.001 par value
per share, of NxStage, at a purchase price of $10.00 per share, for an aggregate purchase price of
$20,000,000 pursuant to the terms of the Stock Purchase Agreement
dated as of February 7, 2007
by and between NxStage and DaVita (the Stock Purchase
Agreement). The Shares represent approximately seven percent
(7%) of NxStage's issued and outstanding shares of common stock.
Registration Rights Agreement
In connection with the issuance of the Shares, NxStage and DaVita entered into a Registration
Rights Agreement dated as of February 7, 2007. Pursuant to the Registration Rights
Agreement, NxStage has agreed to file a registration statement on Form S-3 with respect to the
resale by DaVita of the Shares, and to grant DaVita certain piggyback registration rights.
Item 3.02.
Unregistered Sales of Equity Securities.
The information contained in Item 1.01 above with respect to the sale and issuance of the
Shares to DaVita is incorporated herein by reference.
NxStage is issuing the Shares to DaVita in reliance on the exemption from the registration
provisions of the Securities Act of 1933, as amended, set forth in Section 4(2) promulgated
thereunder
2